Media coverage about BeyondSpring (NASDAQ:BYSI) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BeyondSpring earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.3183391214661 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

BYSI has been the subject of several analyst reports. Zacks Investment Research upgraded BeyondSpring from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of BeyondSpring in a research report on Monday, August 21st. Finally, Maxim Group initiated coverage on BeyondSpring in a research report on Tuesday, August 22nd. They set a “buy” rating and a $52.00 target price for the company.

BeyondSpring (NASDAQ BYSI) opened at $34.07 on Thursday. BeyondSpring has a 52-week low of $16.55 and a 52-week high of $48.49.

BeyondSpring (NASDAQ:BYSI) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.01. equities analysts predict that BeyondSpring will post -4.41 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect BeyondSpring (BYSI) Share Price” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Insider Buying and Selling by Quarter for BeyondSpring (NASDAQ:BYSI)

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.